

Newsletter



European
Reference
Network

Genetic Tumour Risk Syndromes
(ERN GENTURIS)

November 2020 | www.genturis.eu

ERN GENTURIS - upcoming webinars and EJP RD fellowship exchange

In this newsletter we would like to announce the next two upcoming webinars on **pheochromocytoma/paraganglioma** and **hereditary gastric cancer**. For more information, please, see this newsletter. For more information about all planned webinars, please visit our website.

Also, the **Research Mobility Fellowship Call of the European Joint Programme for Rare Diseases is now open** and will be closed on 13 November. More information can be found in this newsletter. Please, share the news amongst PhD students and medical specialists in training in your ERN (affiliated) institution.

We hope we may welcome you (again) during one of our webinars!

2nd Call Research Mobility Fellowship is now open! Apply before 13 November!

The call for Research Mobility Fellowships aims to financially support PhD students and medical doctors in training working in ERN-Full Member or Affiliated Partner institutes to undertake short scientific visits (secondments) fostering specialist research training outside their countries of residence and within one of the ERN-Full Member or Affiliated Partner institutes.

PhD students and medical specialists in training, who have finished their first year of training, can apply for a fellowship within this call. The duration of these short scientific visits (secondments) can be 1 to 3 months and the research training must be completed within 18 months after the application approval.

Applicants that are selected will receive a reimbursement for travel up to 400€ for the entire fellowship and accommodation expenses up to 2000€ per month.

For more information on the call, please visit

<https://www.ejprarediseases.org/index.php/training-and-empowerment/ern-trainings/>



Pheochromocytoma/ paraganglioma – benefit of combined germline and tumour testing for PPGL patients

11 November - 16:00 CET
Prof. Evelin Schröck, Dresden

Every patient afflicted with a PPGL tumour should be offered genetic testing, since germline mutations are found in 30% of all PPGL patients and in 80% of young PPGL patients. Integration of germline and tumour sequencing data greatly benefits patients by enhancing detection rates of pathogenic variants. Tumour sequencing is imperative for the identification of potential somatic driver mutations and potential exclusion of hereditary tumour syndromes. This is of importance for patients and their families. Surveillance programs and clinical management programs are needed. The establishment of in vitro models enables fast analysis of VUS in SHDB, VHL and FH (PoC). The aim is to streamline classification of VUS identified in PPGL patients, which contributes to precision cancer medicine. If you would like to join this webinar, register [here](#).

Hereditary Gastric Cancer

25 November - 16:00 CET
Dr. Carla Oliveira, Porto

Hereditary gastric cancer accounts for 1-3% of the global burden of gastric cancer and comprises two major genetically explained syndromes: Hereditary Diffuse Gastric Cancer (HDGC) and Gastric



Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS).

Additionally Familial Intestinal Gastric Cancer, also believed to be genetically determined remains unresolved. The risk of gastric cancer development is high in HDGC families, mainly if these are carriers of germline causing variants in CDH1 (E-cadherin) and CTNNA1 (alpha-E-catenin) genes; and in GAPPS families mainly if these carry germline causing variants in the APC promoter 1B. The current knowledge on the genetics, pathogenesis and clinical aspects of hereditary gastric cancer syndromes will be presented in this webinar. If you would like to join this webinar, register [here](#).

Upcoming webinars:

11 November: Pheochromocytoma/paraganglioma – *Prof. Evelin Schröck*

25 November: Hereditary Gastric Cancer – *Prof. Carla Oliveira*

9 December: PTEN hamartoma tumour syndrome – *Prof. Nicoline Hoogerbrugge*

13 January: Gastrointestinal polyposis syndromes – *Prof. Stefan Aretz*

27 January: Variants identified in tumours can be germline – when to refer for germline testing – *Prof. Kathleen Claes*

10 February: Germline mutations as a therapeutic target in breast cancer - *Dr. Judith Balmaña*

24 February: Cancer Genetic Counseling and previvorship in an Era of Rapid Change – *Dr. Ignacio Blanco*

17 March: Von Hippel-Lindau Syndrome – *Prof. Eamonn Maher*

31 March: Psycho-oncologic aspects of genetic tumour risk syndromes – *Prof. Yvonne Brandberg*

For more information on these webinars or for registration, please visit the [ERN GENTURIS website](#).

ERN GENTURIS Coordinating Center:

Radboud university medical center
The Netherlands

How to unsubscribe?

You received this newsletter because you are a contact of ERN GENTURIS. If you no longer wish to receive newsletters, please [unsubscribe](#).

genturis@radboudumc.nl
<https://www.genturis.eu>

© Radboudumc

